The HEPLISAV-B Pregnancy Registry is an observational research study for women who were vaccinated with HEPLISAV-B within 28 days prior to conception, or during their pregnancy. The goal of the registry is to learn more about the health of infants born to mothers exposed to HEPLISAV-B during pregnancy. The information collected will provide doctors with an understanding of the effect (if any) of HEPLISAV-B exposure during pregnancy.
HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.
References: 1. HEPLISAV-B [package insert]. Emeryville, CA: Dynavax Technologies Corporation; 2020.2. Dynavax’s HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults [news release]. Emeryville, CA: Dynavax Technologies Corporation. http://investors.dynavax.com/news-releases/newsrelease-details/dynavaxs-heplisav-btm-hepatitis-b-vaccine-recombinant-adjuvanted. Accessed March 15, 2018.